General Principles of Pharmacology

Correct Answer

D — Full agonist

Rationale

A full agonist binds to a receptor and activates it to produce the maximum possible response that the receptor system can generate. Morphine is the prototypical full agonist at mu-opioid receptors — at sufficient concentration it produces maximal analgesia and maximal receptor activation. A partial agonist binds and activates the receptor but cannot produce the maximum response even at full receptor occupancy. A competitive antagonist binds to the receptor without activating it and blocks agonist access. An inverse agonist binds to the receptor and produces the opposite effect to an agonist.

Correct Answer

B — Partial agonist

Rationale

A partial agonist binds to a receptor and activates it but has intrinsic efficacy less than that of a full agonist — it cannot produce the maximum response the receptor system is capable of generating, regardless of dose. Buprenorphine is the clinical prototype of a partial opioid agonist: it produces analgesia and opioid effects, but these plateau at a ceiling that is lower than what morphine or other full agonists achieve. This ceiling effect is clinically exploited in opioid use disorder treatment, where it limits overdose risk. Full agonists produce the maximal response. Competitive and non-competitive antagonists do not activate the receptor.

Correct Answer

A — Competitive antagonist

Rationale

A competitive antagonist binds to the same site as the agonist, produces no receptor activation, and blocks agonist access in a reversible manner — so that increasing agonist concentration can overcome the antagonism by mass action. Naloxone exemplifies all three features: it binds mu-opioid receptors without activating them, reverses opioid effects, and can be displaced by high concentrations of opioid agonist. This is why repeat dosing of naloxone may be needed in patients who have taken large opioid overdoses. A non-competitive antagonist binds at a different site and reduces the maximum response regardless of agonist concentration — its effect cannot be overcome by adding more agonist.

Correct Answer

C — G protein-coupled receptor

Rationale

Muscarinic receptors are G protein-coupled receptors — seven-transmembrane domain proteins that transduce extracellular ligand binding into intracellular signals through interaction with heterotrimeric G proteins. Depending on the subtype, they couple to inhibitory G proteins that decrease cyclic adenosine monophosphate or to G proteins that activate phospholipase C. Ligand-gated ion channels open or close an ion channel directly upon ligand binding — the nicotinic acetylcholine receptor at the neuromuscular junction is in this category. Receptor tyrosine kinases autophosphorylate upon ligand binding and activate intracellular signaling cascades — the insulin receptor is a classic example. Nuclear receptors bind lipid-soluble ligands intracellularly and regulate gene transcription — glucocorticoid and thyroid hormone receptors belong to this family.

Correct Answer

D — Nuclear receptor

Rationale

Nuclear receptors are intracellular proteins that bind lipid-soluble ligands, which can diffuse across the cell membrane. After ligand binding, the receptor-ligand complex translocates to the nucleus and acts as a transcription factor, altering the expression of specific genes and thereby changing cellular protein synthesis. Because this mechanism requires new protein synthesis, the onset of pharmacological effects of drugs acting through nuclear receptors is typically hours rather than seconds or minutes. Other nuclear receptors include those for thyroid hormone, estrogen, testosterone, vitamin D, and retinoic acid. G protein-coupled receptors and ligand-gated ion channels produce effects within seconds to minutes by changing ion conductance or second-messenger levels.

Correct Answer

B — Ligand-gated ion channel

Rationale

Ligand-gated ion channels combine a receptor domain and an ion channel in the same protein complex. When the ligand binds, the channel opens within milliseconds, producing rapid changes in membrane potential. The nicotinic acetylcholine receptor is the prototype: acetylcholine binding opens a non-selective cation channel, and the resulting sodium influx depolarizes the endplate to trigger muscle contraction. The speed of this response — milliseconds — distinguishes ligand-gated ion channels from G protein-coupled receptors (seconds to minutes) and nuclear receptors (hours). Gamma-aminobutyric acid type A receptors and glycine receptors are also ligand-gated ion channels.

Correct Answer

A — The partial agonist produces a submaximal response even at full receptor occupancy

Rationale

Intrinsic efficacy is the property that determines how effectively a drug activates a receptor once bound. A full agonist has high intrinsic efficacy and produces the maximum response the system can generate. A partial agonist has lower intrinsic efficacy: even when it occupies all available receptors, it cannot drive the receptor to the same degree of activation as a full agonist, so the maximum response is lower. A partial agonist does produce a response — it has some intrinsic efficacy, distinguishing it from an antagonist, which has none. The affinity of a partial agonist for the receptor is independent of its intrinsic efficacy; high affinity does not translate to high efficacy.

Correct Answer

C — The dose-response curve shifts to the right with the maximum response preserved, because sufficient agonist can overcome the antagonism

Rationale

Competitive antagonists compete with agonists for the same binding site in a reversible manner. At any given antagonist concentration, increasing the agonist concentration shifts the equilibrium back toward agonist binding — the antagonism is surmountable. On a dose-response curve, this appears as a parallel rightward shift: more agonist is needed to achieve any given response, but the same maximum response is still achievable at high enough agonist concentrations. This is the pharmacological definition of surmountable or competitive antagonism. Non-competitive antagonists, by contrast, reduce the maximum response regardless of agonist concentration — their antagonism cannot be overcome by increasing agonist dose.

Correct Answer

B — Reduction in maximum response that cannot be overcome by increasing agonist concentration

Rationale

Non-competitive antagonists bind at sites other than the agonist binding site and reduce the receptor's capacity to generate a response, regardless of how much agonist is present. Because the agonist and non-competitive antagonist are not competing for the same site, adding more agonist does not displace the antagonist or restore the maximum response — the antagonism is insurmountable. On a dose-response curve, non-competitive antagonism depresses the maximum (ceiling) response while having variable effects on the apparent potency of the agonist. This is in direct contrast to competitive antagonism, which shifts the curve rightward while leaving the maximum intact.

Correct Answer

D — Drug X is more potent than Drug Y because it achieves the same effect at a much lower dose

Rationale

Potency refers to the dose required to produce a given level of effect — it is quantified as the median effective dose, the dose that produces 50% of the maximum response. The drug that achieves a given effect at a lower dose is more potent. Drug X requires only 1 mg to achieve 50% of maximum effect, compared with 100 mg for Drug Y — so Drug X is 100 times more potent. Potency and efficacy are independent concepts: both drugs produce the same maximum response, so they have equal efficacy. A larger dose requirement indicates lower potency, not greater potency or greater efficacy.

Correct Answer

A — Drug B has greater efficacy than Drug A

Rationale

Efficacy (or maximal efficacy) refers to the maximum pharmacological effect a drug can produce, regardless of dose. Drug B can relieve severe pain — its maximal effect is greater than that of Drug A, which is limited to mild to moderate analgesia even at the highest tolerable dose. Drug A behaves as a partial agonist relative to Drug B. Because both drugs require similar doses to reach their respective maxima, potency is similar and does not explain the difference. The therapeutic index and bioavailability are not described in the scenario and do not account for the difference in maximum analgesic effect.

Correct Answer

C — The first drug has a narrow therapeutic index, leaving little margin between effective and toxic doses

Rationale

The therapeutic index is the ratio of the median toxic dose to the median effective dose. The first drug has a therapeutic index of 2 (4 divided by 2) — the toxic dose is only twice the effective dose, so small increases in dose or drug exposure rapidly enter the toxic range. The second drug has a therapeutic index of 100 (200 divided by 2) — there is a very wide margin between effective and toxic doses, and dosing errors are much less likely to cause harm. Drugs with narrow therapeutic indices such as digoxin, warfarin, lithium, and aminoglycoside antibiotics require plasma concentration monitoring and careful individualized dosing. Bioavailability, agonist type, and metabolism are not described in the scenario.

Correct Answer

B — Reduction in receptor number through internalization and down-regulation in response to sustained agonist exposure

Rationale

Prolonged activation of a receptor by an agonist triggers adaptive changes in the cell that reduce sensitivity to further stimulation — a process called pharmacological tolerance. One major mechanism is receptor down-regulation: sustained agonist exposure causes receptors to be internalized from the cell surface and degraded, reducing the total number of receptors available for activation. With fewer receptors, the same drug concentration produces a smaller response, requiring a dose increase to maintain the original effect. The opposite process — receptor up-regulation — occurs with prolonged antagonist exposure, explaining why abrupt discontinuation of some antagonists can cause rebound effects. Drug metabolism does not convert a full agonist to a partial agonist.

Correct Answer

D — Chronic receptor blockade led to beta-receptor up-regulation, so that when the antagonist is removed, normal catecholamine stimulation produces an exaggerated response

Rationale

When a receptor is chronically blocked by an antagonist, the reduced receptor activation signals the cell to synthesize more receptors — a compensatory adaptation called up-regulation. During beta-blocker therapy, the patient functions normally because the up-regulated receptors remain blocked. When the drug is abruptly withdrawn, the normal level of endogenous catecholamines now acts on a larger-than-normal receptor population, producing an exaggerated adrenergic response: tachycardia, hypertension, and in susceptible patients, angina or myocardial infarction. This is why beta-blockers must be tapered gradually rather than stopped abruptly, particularly in patients with coronary artery disease.

Correct Answer

C — Propranolol blocks beta-2 adrenergic receptors in the airway, removing the bronchodilatory tone of endogenous catecholamines

Rationale

Propranolol is a non-selective beta-adrenergic blocker that blocks both beta-1 receptors in the heart and beta-2 receptors in bronchial smooth muscle. In healthy patients, endogenous epinephrine provides tonic bronchodilation through beta-2 receptor activation. When propranolol blocks these receptors, this bronchodilatory tone is removed — and in a patient with asthma whose airways are already hyperreactive, the loss of beta-2-mediated bronchodilation can precipitate severe bronchoconstriction. This is why non-selective beta-blockers are contraindicated in asthma and chronic obstructive pulmonary disease. Cardioselective beta-1 blockers carry lower but not absent risk.

Correct Answer

A — Naloxone competitively displaces opioids from mu-opioid receptors, restoring normal receptor signaling

Rationale

Naloxone is a competitive antagonist at opioid receptors with very high receptor affinity. It competes with opioid agonists for the same binding site and, because of its high affinity, rapidly displaces opioids from receptor binding sites. With opioids no longer occupying the receptors, the inhibitory opioid signal on brainstem respiratory centers is removed and spontaneous breathing resumes. The competitive nature of the antagonism means that naloxone's effect can be overcome if opioid concentrations are very high — which is why repeated dosing or a continuous infusion may be needed in large overdoses. Naloxone has no action at adrenergic receptors and does not alter hepatic metabolism.

Correct Answer

D — Chronic beta-receptor blockade led to receptor up-regulation, so that when propranolol is removed, normal catecholamine levels produce an exaggerated adrenergic response

Rationale

During chronic beta-blocker therapy, the persistent blockade of beta-adrenergic receptors signals cells to synthesize more receptors — up-regulation — as a compensatory adaptation. While propranolol is present, these additional receptors remain blocked and the patient is clinically stable. When propranolol is abruptly withdrawn, normal circulating levels of epinephrine and norepinephrine now act on an expanded receptor population, producing an exaggerated adrenergic response: tachycardia, hypertension, and in patients with coronary disease, angina or myocardial infarction. This withdrawal syndrome is a direct consequence of receptor up-regulation during chronic antagonist therapy and is the reason beta-blockers should always be tapered gradually.

Correct Answer

B — As a partial agonist, buprenorphine cannot activate opioid receptors to the maximum degree even at very high doses, limiting respiratory depression

Rationale

Buprenorphine's partial agonist property means its intrinsic efficacy at opioid receptors is less than that of full agonists such as morphine, heroin, or fentanyl. Even at very high doses or concentrations, buprenorphine can only activate receptors to a submaximal degree — the dose-response curve for respiratory depression flattens and reaches a ceiling. This ceiling effect substantially reduces the risk of fatal respiratory depression from buprenorphine overdose alone, compared with the steep dose-response curves of full agonists where increasing dose continues to increase respiratory suppression in a potentially fatal manner. This pharmacodynamic property, combined with its high receptor affinity, makes buprenorphine a valuable tool in opioid use disorder treatment.